Rifaquat Rahman, Lorenzo Trippa, Eudocia Q Lee, Isabel Arrillaga-Romany, Geoffrey Fell, Mehdi Touat, Christine McCluskey, Jennifer Wiley, Sarah Gaffey, Jan Drappatz, Mary R Welch, Evanthia Galanis, Manmeet S Ahluwalia, Howard Colman, L Burt Nabors, Jaroslaw Hepel, Heinrich Elinzano, David Schiff, Ugonma N Chukwueke, Rameen Beroukhim, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Tracy T Batchelor, Mikael L Rinne, Thomas J Kaley, Christine Lu-Emerson, Ingo K Mellinghoff, Wenya Linda Bi, Omar Arnaout, Pier Paolo Peruzzi, Daphne Haas-Kogan, Shyam Tanguturi, Daniel Cagney, Ayal Aizer, Lisa Doherty, Maria Lavallee, Brittany Fisher-Longden, Shanna Dowling, Jack Geduldig, Fiona Watkinson, William Pisano, Seth Malinowski, Shakti Ramkissoon, Sandro Santagata, David M Meredith, E Antonio Chiocca, David A Reardon, Brian M Alexander, Keith L Ligon, Patrick Y Wen
PURPOSE: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid-dependent protein kinase/mammalian target of rapamycin inhibitor]) were simultaneously evaluated against a common control arm...
September 18, 2023: Journal of Clinical Oncology